Impac Medical Systems to acquire Impath products

Impac Medical Systems has set in motion a proposal to purchase certain assets of Impath Inc. for $22 million.

 The definitive agreement would have Impac acquire substantially all assets and certain liabilities of Tamtron Corp. and Medical Registry Services Inc., Impath's PowerPath pathology information management and cancer registry information system businesses.

 Anticipating the addition of the PowerPath pathology information management system, Joseph K. Jachinowski, president and CEO of Mountain View, Calif.-based Impac, said that the company has "viewed this area as a synergistic adjacency to our core oncology management business. Seventy percent of all cases pathologists see are cancer-related and their analysis constitutes the first point in a long chain of cancer information management."

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup